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Introduction: Identification of third-generation, cephalosporin-resistant Enterobacteriaceae (3GC-RE) carriers by rectal
screening at admission seems to be an important step in the prevention of transmission and outbreaks; however,
little is known about its effectiveness. The aim of this study was to evaluate the impact of ‘targeted screening’ at
patient admission to intensive care units (ICUs) on the incidence of 3GC-RE hospital-acquired infections (HAIs) and
compare it to ‘universal screening’.
Methods: We undertook a quasi-experimental study of two ICUs (unit A: intervention group; unit B: control group)
at a university-affiliated hospital between 1 January 2008 and 31 December 2011. In unit A, patients were screened
universally for 3GC-RE at admission during period 1 (1 January 2008 through 30 September 2010). During period 2
(2011 calendar year), the intervention was implemented in unit A; patients transferred from another unit or hospital
were screened selectively. In unit B, all patients were screened throughout periods 1 and 2. 3GC-RE-related HAI
incidence rates were expressed per 1,000 patient-days. Incidence rate ratios (IRRs) were examined by multivariate
Poisson regression modelling.
Results: In unit A, 3GC-RE-related HAI incidence rates decreased from 5.4 (95% confidence interval (CI), 4.1 to 7.0)
during period 1 to 1.3 (95% CI, 0.5 to 2.9) during period 2 (P < 0.001). No changes were observed in unit B between
periods 1 and 2 (P = 0.5). In unit A, the adjusted incidence of 3GC-RE-related HAIs decreased in period 2 compared
with period 1 (adjusted IRR, 0.3; 95% CI, 0.1 to 0.9; P = 0.03) independently of temporal trend, trauma and age. No
changes were seen in unit B (P = 0.4). The total number of rectal swabs taken showed an 85% decrease in unit A
between period 1 and 2 (P < 0.001).
Conclusions: Targeted screening of 3GC-RE carriers at ICU admission was not associated with an increase in
3GC-RE-related HAI incidence compared with universal screening. Total number of rectal swabs decreased significantly.
These findings suggest that targeted screening may be worth assessing as an alternative to universal screening.* Correspondence: philippe.vanhems@chu-lyon.fr
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Third-generation cephalosporin-resistant Enterobacteria-
ceae (3GC-RE), and particularly extended-spectrum β-
lactamase-producing Enterobacteriaceae (ESBL-E), have
become a global concern since the beginning of the 21st
century [1]. The incidence of ESBL-E has increased in
both community and hospital settings [2]. The European
Antimicrobial Surveillance Network has reported major
increases of third-generation cephalosporin-resistant
Escherichia coli proportions in health care institutions,
ranging from 1.7% in 2002 to 8% in 2009 [3]. Similar
trends have been noted with ESBL-E infections by the
French National Surveillance Network for Multidrug-
Resistant Bacteria (BMR-RAISIN). The overall incidence
rate increased between 2002 and 2012 from 0.13 to 0.53
per 1,000 patient-days, and in intensive care units (ICUs)
the incidence rate during the same period increased
from 0.79 to 2.36 per 1,000 patient-days [4], a rate three-
to fivefold higher in ICUs than in non-ICU surgical or
medical departments [4,5]. Control of ESBL-E spread is
therefore urgently required [6].
Many infection control measures, such as contact isola-
tion of patients with colonization or infection, antimicro-
bial stewardship programmes, active screening culture
(ASC) and selective digestive decontamination (SDD),
have been proposed to control bacterial transmission [7].
According to a report of a French study of three ICUs, an
ESBL-E outbreak was controlled by the association of
ASC for all patients at admission with contact isolation
[8]. Without evidence supporting specific infection control
strategies, no definite guidelines can be implemented in
nonoutbreak settings [9]. Only general recommendations
on the control of Gram-negative organisms are currently
available [10,11]. A 2011 literature review revealed a
dearth of research on the control of ESBL-E transmission
in hospitals [12]. The lack of evidence-based guidelines,
with disparities in infection control practices, may be fac-
tors behind the increase in ESBL-E incidence [13].
The importance of ASC is unclear in the absence of out-
breaks [14]. ‘Universal screening’ is costly and may not be
needed when patient-to-patient transmission [15] and
prevalence of carriage at patient admission are low [16].
An option is ‘targeted surveillance’ of patients with severe
underlying disease or risk factors for ESBL-E carriage at
admission [17,18]. Recent studies have implicated several
risk factors for ESBL-E colonization at admission: prior
ESBL-E carriage, transfer from hospitalization units and
especially long-term care facilities or ICUs, coming from a
high-prevalence country, poor functional status, current
antibiotic use and chronic renal insufficiency [14,17,19-23].
In our institution, universal screening is performed at
ICU admission. In 2010, targeted screening at ICU ad-
mission for patients transferred from another unit or
hospital was implemented in one of the ICUs because ofhigh costs and resource constraints. We hypothesized
that this targeted screening at admission does not in-
crease 3GC-RE-related hospital-acquired infection (HAI)
incidence rates in ICUs compared with universal screen-
ing and might therefore represent an interesting strategy.
The total number of rectal swabs should decrease with tar-
geted screening. The aim of the present study was to as-
sess the impact of targeted screening at ICU admission on
3GC-RE-related HAI incidence in a quasi-experimental
setting.
Material and methods
Setting, subjects and design
We performed a 3-year quasi-experimental study with
intervention and control groups to evaluate targeted
screening for 3GC-RE at ICU admission. Data were col-
lected prospectively between January 2008 and December
2011 at Edouard Herriot Hospital, an 850-bed university-
affiliated hospital in Lyon, France. Two ICUs located in
separate buildings were included in the study: Unit A, the
intervention group, comprised a polyvalent medical ICU
with 15 single rooms; and unit B, the control group, com-
prised a polyvalent medical-surgical ICU with 12 single
rooms. These two ICUs had a similar staff–patient alloca-
tion. Data from two different time periods were collected.
Figure 1 outlines the study design. Period 1 (pre-test
period) included patients admitted between 1 January
2008 and 30 September 2010. During this time period,
both units A and B undertook universal screening for
3GC-RE at patient admission. The intervention was the
implementation of targeted screening for 3GC-RE at pa-
tient admission in the last quarter of 2010 in unit A. After
the intervention, the posttest period (period 2) included
patients admitted between 1 January 2011 and 31 Decem-
ber 2011. Targeted screening for 3GC-RE at patient ad-
mission was implemented in unit A. During this period,
unit B maintained universal screening for 3GC-RE at pa-
tient admission. The last quarter of 2010 was a wash-out
period for targeted screening in unit A. The incidence
rates of overall HAIs and 3GC-RE-related HAIs and the
total number of rectal swabs between the two time periods
were compared to assess the effectiveness of targeted
screening.
The two study ICUs have participated in the French Na-
tional HAI Surveillance Network in Intensive Care Units
(Réseau REA-RAISIN) since 1999. The programme is de-
scribed in detail in the literature [24-26]. All patients hos-
pitalized for ≥48 hours in either unit A or B during the
study period (except for the washout period at the end of
2010) were included in the national surveillance network
and participated in the study. Data were collected pro-
spectively by the hospital infection control team (nurses
and physicians), and feedback was provided annually to
ICU physicians and nurses. Furthermore, a team member
U: Universal screening for 3GC-RE
T: Targeted screening for 3GC-RE
Unit A:  Intervention 
group
Intervention: « targeted screening » for 3GC-RE
Third quarter of 2010 : wash-out period
Unit B: Control group
Period #1 Period #2 
TU
2008          2009            2010            2011          2012
UU
2008          2009            2010           2011          2012
Figure 1 Design of the quasi-experimental study in two intensive care units of Edouard Herriot Hospital, Lyon, France, 2008 through
2011. The intervention group was unit A, in which targeted screening for 3GC-RE at patient admission was implemented at the end of 2010. The
control group was unit B, in which universal screening at patient admission was performed throughout the study period. Period 1 comprised
patients admitted between 2008 and the third quarter of 2010. Period 2 comprised patients admitted in the 2011 calendar year.
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prevention practices. Infection control strategies were
similar in both units during the surveillance periods,
and written protocols were available. Universal precau-
tions (including regular hand hygiene with alcohol-based
solution and wearing gloves and gown during activities
likely to generate contact with body fluids) were applied
throughout the study. Barrier precautions (that is, rigor-
ous handwashing, strict use of gowns and gloves) were
enforced for all 3GC-RE-positive patients, as recom-
mended by the Centers for Disease Control and Preven-
tion [27]. Counselling by the expert infection control
team was similar during the surveillance period. No edu-
cational programmes were engaged in during the study.
Definitions of active screening culture and
microbiological methods
Universal screening for 3GC-RE was defined as rectal
swab screening ≤48 hours after patient admission. All
patients submitted to contact isolation pending the re-
sults. If samples were negative for 3GC-RE, contact iso-
lation was lifted and rectal swabs were repeated weekly
until patient discharge. Contact isolation was maintained
if samples were 3GC-RE-positive.
Targeted screening for 3GC-RE was defined as rectal
swab screening ≤48 hours after admission only for pa-
tients transferred from another unit or hospital to the
ICU (long-term care facilities and nursing homes in-
cluded). Patients transferred from an emergency depart-
ment were excluded if they were admitted from home.
All screened patients were placed in contact isolation
pending the results. If samples were 3GC-RE-negative,
contact precautions were stopped and rectal swabs were
not repeated weekly. Patients with a history of 3GC-REasymptomatic carriage or infection in their medical re-
cords were directly placed in contact isolation without
sampling. In contrast, patients were not screened for
3GC-RE if they were not transferred from another unit
or hospital to the ICU.
Rectal swabs were taken to detect 3GC-RE and were
plated in 5 mg/L ceftazidime-based Mueller Hinton
medium (BD, Pont de Claix, France). The plates were in-
cubated for 18 to 24 hours in aerobic conditions, and all
colonies with growth in medium were identified by mass
spectrometry (Saramis; bioMérieux, Marcy l’Etoile, France).
Carriers were defined as patients from whom 3GC-RE
was recovered from screening samples. The results of
screening cultures for 3GC-RE were analysed by using
the MOLIS laboratory information system (vision4health,
Paris, France).
Definitions of overall HAIs and 3GC-RE-related HAIs
Overall HAIs and 3GC-RE-related HAIs were recorded in
accordance with surveillance network definitions, are
based on national guidelines of the French Ministry of
Health [28], and in accordance with European Centre for
Disease Prevention and Control definitions [29]. Three
HAI types were included in the REA-RAISIN and then in
the surveillance: pneumonia, urinary tract infections and
bacteraemia. Only the first HAI occurring >48 hours after
patient admission was taken into account. All types
of bacteria may have been implicated in overall HAIs.
3GC-RE was defined as Enterobacteriaceae resistant to
third-generation cephalosporins, regardless of the factor
contributing to cephalosporin resistance (that is, extended-
spectrum β-lactamase (ESBL) or overproduction of cepha-
losporinase). 3GC-RE-related HAI was defined by the
identification of at least one 3GC-RE in a clinical sample.
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criteria:
1. Two chest X-rays exhibiting lung infiltrates; and
2. At least one of the following clinical signs:a. Hyperthermia (>38°C) without any other cause
and/or
b. Leucopenia (leucocyte count <4,000 white blood
cells (WBCs)/mm3) or leucocytosis (leucocyte
count >12,000 WBCs/mm3); and
3. At least one of the following:
a. Onset of purulent secretions or changes in
characteristics,
b. Findings suggestive of auscultation and/or
c. Cough, dyspnoea or tachypnoea and
d. Low oxyhaemoglobin saturation or increased
pulmonary oxygen consumption; and
4. Diagnostic method:
a. Directed bronchoalveolar lavage (BAL)–positive
culture at a threshold of 104 colony forming units
(cfu)/ml in BAL or 103 cfu/ml in mini-BAL,
b. Fibre-optic bronchoscopy specimen-positive
culture at a threshold of 106 cfu/ml or
c. One of the following alternative methods: positive
blood culture without any other sources of
infection, positive culture of pleural fluid, pleural
or lung abscess with positive culture or
histological evidence of pneumonia.
Urinary tract infection was defined by the following
criteria:
1. Fever (>38°C), feeling of urinary urgency, frequent
urination, dysuria, burning sensation, suprapubic
pain in the absence of any other cause, infectious or
noninfectious ; and
2. With current catheterization or catheterization in
the preceding 7 days: positive urine culture
(≥105 cfu/ml) and, at the most, two different
microorganisms; and
3. Without catheterization: leucocyturia (≥104 cells/ml)
and positive urine culture (≥103 cfu/ml) and, at the
most, two different microorganisms.
Bacteraemia was defined as an association of clinical
signs and at least one positive blood culture isolate. Two
positive blood cultures with the same microorganism
were needed for the following microorganisms: coagulase-
negative staphylococci, Bacillus spp. (except Bacillus
anthracis), Corynebacterium spp., Propionibacterium spp.,
Micrococcus spp. or other saprophytic or commensal
microorganisms with comparable pathogenic potential.
Blood cultures should be collected from different sites and
at different times (maximum of 48 hours is usual).Statistical analysis
The continuous variables evaluated were as follows: length
of ICU stay (days), age (years), Simplified Acute Physiology
Score II (SAPS II), length of mechanical ventilation and
urinary catheterization (days). These variables were ana-
lysed as mean and standard deviation (SD). Age and SAPS
II were further grouped and coded for analysis by age
group (0 to 44, 45 to 59, 60 to 74 and 75+ years) and SAPS
II (scores: 0 to 29, 30 to 39, 40 to 49 and 50+). The cat-
egorical variables analysed included sex, antibiotics re-
ceived at admission, patient origin, diagnostic category at
admission, trauma patients (with or without surgical inter-
vention), immunodeficiency, invasive devices and in-
hospital death. Analyses were conducted with Stata 11.0
software (StataCorp, College Station, TX, USA).
Descriptive analysis of the study population was
undertaken. It was supplemented by analysis of the unit
population over time. Analyses for trends in the inci-
dence of overall HAIs and 3GC-RE-related HAIs were
performed. Qualitative variables are reported as number
of individuals and percentage, with the χ2 or Fisher’s
exact test used as appropriate. Quantitative variables are
reported as mean and SD and were analysed by t-test.
The attack rate was defined as the number of overall
HAIs or 3GC-RE-related HAIs per 100 patients, and in-
cidence was defined the number of HAIs per 1,000
patient-days at risk. The evolution of the number of rec-
tal swabs and the number of patients sampled at admis-
sion in the two units before and after the intervention
were modelled by a Poisson regression that included the
number of samples, the time trend (in months) and the
period (1 or 2).
The Poisson regression modelled the effect of time
trends on 3GC-RE-related HAI incidence rates. In these
regression analyses, HAI rates were dependent variables,
and time trends (in quarters) and period were independ-
ent variables. The potential confounders tested were sex,
age category, SAPS II, diagnostic category at admission,
patient origin, diagnostic category, central venous cathe-
terization, mechanical invasive ventilation, urinary cathe-
terization and antibiotics received at admission. Time
trend and period were forced into the model for multi-
variate analysis. Other variables were introduced in
multivariate analysis if P < 0.15 in univariate analysis.
The final model contained the two independent variables
and all the potential confounders. P < 0.05 was consid-
ered as statistically significant.
Ethics statement
The study did not require ethics committee approval,
because it was based on an observational surveillance
database approved under French national regulations
(Comité National Informatique et Liberté). Written con-
sent was not obtained from patients, because we carried
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anonymously and patient care was not affected.
Results
Patient characteristics
Over the 3-year study period, 2,915 patients in both
ICUs were hospitalized for ≥48 hours. Among them, 189
(6.5%) were hospitalized in the last quarter of 2010 and
were therefore excluded. One hundred sixty-eight pa-
tients (6.2%) had one or more missing values and were
also excluded; of these, 99 (5.6%) were hospitalized in
unit A and 69 (7.1%) in unit B (P = 0.1). Ultimately,
2,558 patients, accounting for 25,769 patient-days, were
included in the study: 1,756 (68.6%) patients accounted
for 15,149 patient-days in unit A, and 802 (31.4%) pa-
tients accounted for 10,620 patient-days in unit B.
In the study population, 1,604 (62.7%) were male, 1,631
(63.8%) received antibiotics at admission, 1,115 (43.6%)
came from home and 775 (30.1%) were immunosup-
pressed. The mean age was 61.1 ± 16.7 years (median age,
63 years; interquartile range, 51 to 74), and the mean
SAPS II was 47.6 ± 19.7. The mean length of hospital stay
was 10.1 ± 17.0 days; it was 8.9 ± 17.8 days for invasive
mechanical ventilation and 9.2 ± 14.6 days for urinary
catheterization.
Table 1 describes patient characteristics by unit and
time period. Some characteristics differed between periods
1 and 2. In unit A, the proportions of patients differed be-
tween the two periods as follows: trauma patients, intu-
bated patients and patients with urinary catheters; patient
origin; proportion of antibiotic therapy at admission; and
mean duration of stay, of intubation and of urinary
catheterization. The proportions differed over time in unit
B in the following groups: the proportions of trauma, intu-
bated and catheterized patients; the proportions of those
on antibiotic therapy at admission and of immunode-
pressed patients; patient origin and diagnostic category;
and mean age and SAPS II.
Overall, 149 patients (5.8%) developed Enterobacteria-
ceae-related HAIs. For 23 of these patients, antibiotic re-
sistance of the identified bacteria was not tested (P = 0.06
between period 1 and 2). 3GC-REs were identified in 86
(3.4%) of 149 infected patients: 61 (3.7%) in unit A and 25
(2.8%) in unit B. Among these patients, 50 (58.1%) were
admitted from another hospital unit. Ninety-three 3GC-
REs were isolated from clinical samples, 13 (14.0%) of
them were both 3GC- and carbapenem-resistant. The
most common bacteria isolated in 3GC-RE-related
HAIs were Klebsiella spp. (n = 24, 37.0%) in unit A
and Escherichia coli (n = 9, 32.1%) in unit B. Attack
rates of first 3GC-RE-related HAIs per 100 admissions
were comparable in units A and B (P = 0.24). Never-
theless, the incidence rate of 3GC-RE-related HAIs
per 1,000 patient-days was statistically higher in unitA (4.3; 95% CI, 3.3 to 5.5) than in unit B (2.5; 95%
CI, 1.7 to 3.7) (P = 0.03).
Effect of targeted screening for 3GC-RE on HAI incidence
Table 1 reports attack and incidence rates of overall
HAIs and 3GC-RE-related HAIs. In both units, inci-
dence rates of overall HAIs remained stable during
period 1 compared with period 2 (P = 0.29 in unit A, P =
0.71 in unit B). Incidence rates of overall HAIs by year
and by unit are shown in Figure 2A. In unit A, the inter-
vention group, the 3GC-RE-related HAI incidence rate de-
creased from 5.4 (95% CI, 4.1 to 7.0) during period 1 to
1.3 (95% CI, 0.5 to 2.9) during period 2 (P < 0.001). In unit
B, the control group, the 3GC-RE-related HAI incidence
rate remained stable during period 2 compared with
period 1 (P = 0.48). 3GC-RE-related HAI incidence rates
by year and by unit are shown in Figure 2B.
The results of multivariate Poisson regression analysis
are presented in Table 2. Age and trauma patients were
found to have a significant effect (P < 0.05) and were
retained in the final multivariate model. The multivariate
model was forced with temporal trend and period. Adjusted
incidence decreased after implementation of targeted
screening in unit A (incidence rate ratio (IRR) = 0.28; 95%
CI, 0.09 to 0.88; P = 0.03). No decrease was shown in unit
B between periods 1 and 2 (P = 0.40).
Effect of targeted screening on the number of rectal
swabs sampled
In total, 2,899 rectal swabs were collected in both ICUs:
1,112 (38.5%) in unit A and 1,787 (61.6%) in unit B. A
total of 1,589 samples were collected at admission. One
hundred eighteen (7.4%) of screened patients tested
positive for 3GC-RE at admission during the study
period: 64 (8.0%) in unit A and 54 (6.4%) in unit B (P = 0.4).
Table 3 describes the different 3GC-REs identified from
rectal swabs at patient admission. The most common
bacteria isolated at patient admission were Klebsiella spp.
(n = 26 bacteria, 40.6%) in unit A and Escherichia coli
and Enterobacter spp. (n = 16 bacteria, 29.6%) in unit B.
Among the 1,471 (92.6%) patients with negative 3GC-RE
cultures at admission, 85 (5.8%) acquired 3GC-RE
colonization: 32 (4.3%) in unit A and 53 (7.2%) in unit B
(P = 0.02). Among the 118 (7.4%) patients colonized with
3GC-RE at admission, 22 (18.6%) of colonized patients
subsequently had negative cultures and 88 (74.6%) re-
mained colonized. Data about the clinical evolution of in-
fection during the stay were found for 99 patients (84%
of colonized patients at admission). Fifty-seven (57.6%)
patients were admitted from another hospitalization unit
or nursing home. Eleven (11.1%) developed an infection
due to 3GC-RE during the stay. Among these 11 patients,
8 (72.7%) were admitted from another hospitalization
unit.
Table 1 Study population and hospital-acquired infection incidence rates by unit and time perioda
Variables















Categorical variables, n (%)
Male sex 669 (60.3) 348 (63.0) 0.28 430 (66.6) 157 (62.8) 0.29
Antibioticsd 759 (68.4) 436 (79.0) <0.001 288 (44.6) 148 (59.2) <0.001
Trauma patients 44 (4.0) 8 (1.5) 0.006 137 (21.2) 15 (6.0) <0.001
Diagnostic categoryd 0.14 0.004
Medical ICU 1,030 (92.8) 522 (94.6) 248 (38.4) 121 (48.4)
Emergency surgical ICU 50 (4.5) 14 (2.5) 181 (28.0) 46 (18.4)
Scheduled surgical ICU 30 (2.7) 16 (2.9) 217 (33.6) 83 (33.2)
Patient origind <0.001 0.005
Home or nursing home 473 (42.6) 437 (79.2) 140 (21.7) 65 (26.0)
Short-stay unit 559 (50.4) 103 (18.7) 404 (62.5) 146 (58.4)
Long-stay unit 29 (2.6) 7 (1.3) 24 (3.7) 0 (0.0)
ICU 49 (4.4) 5 (0.9) 78 (12.1) 39 (15.6)
Immunodeficiencyd 243 (21.9) 102 (18,5) 0.16 329 (51.0) 101 (40.4) 0.014
Invasive mechanical ventilation 800 (72.1) 369 (66.9) 0.03 442 (68.4) 131 (52.4) <0.001
Central venous catheterization 737 (66.4) 383 (69.4) 0.22 518 (80.2) 220 (88.0) 0.006
Urinary catheterization 1,027 (92.5) 494 (89.5) 0.04 557 (86.2) 217 (86.8) 0.82
Died in-hospital 253 (22.8) 109 (19.8) 0.16 93 (14.4) 37 (14.8) 0.88
Continuous variable, mean (SD)
Length of ICU stay, days 10.1 (15.4) 7.1 (8.5) <0.001 12.1 (22.8) 11.1 (19.0) 0.54
Age, yearsd 61.2 (16.9) 62.7 (16.9) 0.10 59.1 (16.0) 61.8 (16.6) 0.03
SAPS IId 51.7 (19.1) 51.6 (18.3) 0.92 41.2 (20.0) 37.7 (16.3) 0.014
Length of invasive mechanical ventilation, days 8.7 (15.1) 5.7 (7.8) <0.001 11.4 (25.7) 11.0 (20.0) 0.85
Length of urinary catheterization, days 9.7 (14.1) 6.2 (6.5) <0.001 10.6 (19.2) 9.6 (15.8) 0.49
Incidence of overall HAIs
Number of HAIs 149 50 116 38
Attack ratee 13.4 9.1 0.01 18.0 15.2 0.33
Incidence of overall HAIsf (95% CI) 18.0 (15.3 to 21.2) 15.2 (11.3 to 20.0) 0.29 23.5 (19.4 to 28.2) 21.8 (15.5 to 30.0) 0.71
Incidence of 3GC-RE-related HAIs
Number of 3GC-RE-related HAIs 56 5 20 5
Attack ratee 5.1 0.9 <0.001 3.1 2.0 0.37
Incidence of 3GC-RE-related HAIsf (95% CI) 5.4 (4.1 to 7.0) 1.3 (0.4 to 3.0) <0.001 2.8 (1.7 to 4.3) 1.9 (0.6 to 4.5) 0.48
aCI, Confidence interval; 3GC-RE-related HAIs, Hospital-acquired infections (pneumonia, urinary tract infections and bacteraemia) with identification of third-generation
cephalosporin-resistant Enterobacteriaceae in at least one clinical sample; ICU, Intensive care unit; Overall HAIs, Overall hospital-acquired infections (pneumonia, urinary
tract infections and bacteraemia); SAPS II, Simplified Acute Physiology Score II; SD, Standard deviation. bUniversal screening. cTargeted screening. dAt admission. ePer 100
patients. fPer 1,000 patient-days.
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CI, 80.0% to 88.2%; P < 0.001) in unit A between periods
1 and 2. No decrease was observed in unit B during
period 2 (P = 0.44). The number of patients screened for
3GC-RE at admission and proportions of patients with
3GC-RE carriage detected at admission are shown in
Figure 3 by year and by time period. The number ofpatients screened for 3GC-RE at admission decreased by
80.0% (95% CI, 73.7% to 84.9%; P < 0.001) between pe-
riods 1 and 2 in unit A. Conversely, no decline was ap-
parent in unit B between periods 1 and 2 (P = 0.42). In
unit A, the proportion of patients with 3GC-RE carriage
detected at admission among screened patients was sig-
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Figure 2 Trends of overall and third-generation, cephalosporin-resistant Enterobacteriaceae–related hospital-acquired infections by
period and by unit. (A) Trends of overall hospital acquired infections (HAIs) by period and unit are depicted. Note: For each unit, the incidence
rate per year (2008, 2009 and 2010) was compared with the rate in 2011. The intervention group was unit A with targeted screening for 3GC-RE
at patient admission at the end of 2010. The control group was unit B with universal screening at patient admission throughout the study. Period
1 comprised patients admitted between 2008 and the third quarter of 2010. Period 2 comprised patients admitted in the 2011 calendar year. In
both units, the overall HAI incidence rate remained stable over time. (B) Third-generation, cephalosporin-resistant Enterobacteriaceae (3GC-RE)–
related HAI trends by period and unit are shown. *P < 0.05. **P < 0.001. For each unit, the incidence rate per year (2008, 2009 and 2010) was
compared with the rate in 2011. The intervention group was unit A with targeted screening for 3GC-RE at the end of 2010. The control group
was unit B with universal screening throughout the study. Period 1 comprised patients admitted between 2008 and the third quarter of 2010.
Period 2 comprised patients admitted in 2011. In unit A, the 3GC-RE-related HAI incidence rate decreased during period 2 compared with each
year of period 1. In unit B, no significant decrease was observed between periods 1 and 2.
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Table 2 Incidence rate ratios of third-generation, cephalosporin-resistant Enterobacteriaceae–related hospital-acquired
infections with multivariate poisson regression analysisa
Variables
Intervention group: unit A Control group: unit B
Adjusted IRR of 3GC-RE HAIs
(95% CI)b P-value
Adjusted IRR of 3GC-RE HAIs
(95% CI)b P-value
Bivariate modelc
Time trend, per quarterd 0.97 (0.89 to 1.06) 0.50 1.05 (0.91 to 1.21) 0.52
Period
Before targeted screeninge 1 1
After targeted screeningf 0.30 (0.098 to 0.94) 0.04 0.50 (0.12 to 2.01) 0.32
Multivariate modelg
Time trend, per quarterd 0.99 (0.91 to 1.08) 0.85 1.01 (0.88 to 1.17) 0.18
Period
Before targeted screeninge 1 1
After targeted screeningf 0.28 (0.090 to 0.88) 0.03 0.54 (0.13 to 2.25) 0.40
a3GC-RE, Third-generation cephalosporin–resistant Enterobacteriaceae; HAI, Hospital-acquired infection; IRR: Incidence rate ratio. bAfter multivariate Poisson regression.
cTime trend (per quarter) and period were forced into the model. d3-month interval. . ePeriod 1 (2008 to 2010). fPeriod 2 (2011). gAdjusted for age and trauma patients.
Time trend (per quarter) and period were forced in the model.
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patients) (P = 0.003). In unit B, no difference was ob-
served over time (P = 0.99).Discussion
Identification of 3GC-RE carriers by rectal screening at
admission seems to be an important step in the preven-
tion of transmission and outbreaks in ICUs; unlike
methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococcus [30,31], however, lit-
tle is known about its effectiveness [12]. The objective of
this study was to evaluate the impact of targeted screen-
ing compared with universal screening at admission on
incidence rates of 3GC-RE-related HAIs in ICUs.
The main finding of this study is the absence of an in-
crease of the incidence density of 3GC-RE-related HAIs
(per 1,000 patient-days) during period 2 (‘targeted screen-
ing’) compared with period 1 (‘universal screening’) in unitTable 3 Description of third-generation, cephalosporin-
resistant Enterobacteriaceae isolated from rectal swabs at
patient admission






Klebsiella pneumoniae 26 (40.6) 14 (25.9) 0.09 40 (33.9)
Enterobacter spp. 19 (29.7) 16 (29.6) 0.9 35 (29.7)
Escherichia coli 13 (20.3) 16 (29.6) 0.3 29 (24.6)
Citrobacter spp. 3 (4.7) 4 (7.4) 0.6 7 (5.9)
Morganella morganii 2 (3.1) 1 (1.9) 0.7 3 (2.5)
Pantoea spp. 0 (0.0) 2 (3.7) 0.2 2 (1.7)
Serratia marcescens 1 (1.6) 0 (0.0) 0.5 1 (0.8)
Hafnia alvei 0 (0.0) 1 (1.9) 0.5 1 (0.8)A, even in multivariate models. A strength of the study is
that HAI surveillance is included in the REA-RAISIN.
Thus, HAI definitions did not change over the study
period, and data collection followed a standardized
protocol, limiting collection bias. Moreover, the study
was carried out in a nonoutbreak setting. Infection con-
trol measures were the same over time (that is, standard
precautions and contact isolation of 3GC-RE-positive
patients).
In addition, the results of our study show that the
number of patients screened for 3GC-RE at admission
decreased in unit A during period 2. Among patients
who tested positive for 3GC-RE carriage at admission,
less than 15% developed an infection due to 3GC-RE.
Conversely, nearly three-fourths of patients who tested
positive for 3GC-RE at admission and became infected
by 3GC-RE during their hospitalization were transferred
from another hospitalization unit. These results reveal
that targeted screening at admission decreased the work-
load of ICU staff and permitted them to target those pa-
tients at greatest risk for 3GC-RE infection among all
patients colonized by C3G-RE at admission.
To avoid patient-to-patient transmission, it may be im-
portant to detect patients colonized by 3GC-RE at ad-
mission to ICUs [17]. For several reasons, universal
screening may not be an optimal ICU strategy. First, the
proportion of patient-to-patient transmissions remains
somewhat unknown and seems to vary from species to
species [32,33]. In some studies, researchers have tried
to evaluate patient-to-patient transmission by analysing
the genetic similarity of isolates, but the results appear
to be discrepant [34]. Moreover, Escherichia coli is increas-
ingly implicated in infections [35], and some evidence of





















































































Unit A Unit B Unit A Unit B
Period #2: « targeted screening »
 in unit Ain units A and B
Period #1: « universal screening » 
Figure 3 Number of patients screened for third-generation, cephalosporin-resistant Enterobacteriaceae at admission and proportion of
patients positive for third-generation, cephalosporin-resistant Enterobacteriaceae. Red columns represent the number of patients screened
for third-generation, cephalosporin-resistant Enterobacteriaceae (3GC-RE) in unit A. Blue columns represent the number of patients screened for
3GC-RE in unit B. The lines represent the proportion of patients positive for 3GC-RE at admission among all screened patients at admission for
each unit. In unit A, the intervention unit, the number of patients screened at admission was divided by 5 between period 1 (universal screening,
2008 to 2010) and period 2 (targeted screening, 2011). The proportion of patients positive for 3GC-RE at admission increased between periods 1
and 2 (P = 0.004). No changes were observed in unit B, the control unit, between periods 1 and period 2 (P = 0.98).
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not appear to be cost-effective for ESBL-E eradication
[16,36]. It was reported to be more than CAD $1 million
in a 2002 study [15]. Thus, targeting patients at risk of
colonization at ICU admission may be worth further as-
sessment as an alternative to universal screening. There is
in choosing criteria for targeted screening at ICU admis-
sion. Transfer from another hospital unit is known to be a
risk factor for 3GC-RE carriage [21]. This criterion was
chosen in unit A in the present study for its simplicity be-
cause transferred patients are easy to identify. However,
other risk factors might be spotlighted according to local
3GC-RE epidemiology. Targeting patients with a high risk
of nosocomial infection and in whom adequate antibiotic
treatment is warranted (for example, patients with severe
trauma, major surgery) is also worth considering [18].
SDD could be viewed as a competing strategy. Indeed,
universal decolonization was found to be more effective
than targeted screening and isolation in reducing rates
of MRSA clinical isolates [37], but its efficacy is not fullyknown in the case of 3GC-RE. Some researchers have
reported positive results with decolonization of carriers
in ICU [38], even if the emergence of resistance was a
particular concern [39].
A 2005 to 2009 Canadian study suggested that the
higher the proportion of screened patients, the lower the
3GC-RE-related HAI incidence rate [40], which could be
explained by a higher number of patients in contact iso-
lation and decreased patient-to-patient transmission.
This assumption runs counter to our results, which
show no increase of the 3GC-RE-related HAI incidence
rate with a lower proportion of screened patients. How-
ever, various individual and facility factors influencing
3GC-RE acquisition might explain the difference [34].
Compliance with barrier precautions, as well as other
noncollected data (such as previous antibiotic therapies),
was not evaluated in our study. Thus, even if our results
may not be extended, targeted screening for 3GC-RE at
ICU admission seemed to be as effective as universal
screening in our study.
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its quasi-experimental design is limited by a lack of ran-
domisation. Randomisation, which requires human and
financial resources, is indeed tricky to implement in
health care settings. The unicentric design does not permit
extension of the data. The key strength of our study is the
prospective nature of surveillance based on a national,
standardized protocol. Moreover, it follows the guidelines
for quasi-experimental study design and statistical analysis
recommended in the literature [41-43], that is, adjustment
on temporal trends and confounding factors. Inclusion of
a control group improves the study’s internal validity.
Given the nature of our study, based on a surveillance
network protocol, we did not collect all confounding fac-
tors described in the literature. Covariables may be in-
complete or unsuitable. For instance, the nature and
duration of antibiotic administration at admission were
not specified. Some comorbidities (such as diabetes
mellitus) were not recorded and could have been con-
founding factors. Some patients’ characteristics changed
between periods 1 and 2 in both ICUs, especially length
of ICU stay, showing that patients hospitalized in both
ICUs changed over time. Nevertheless, the absence of an
increase in the 3GC-RE-related HAI incidence rate was
still apparent after multivariate analysis, which permitted
adjustment for potential confounders. The decreasing
incidence may be due to an unidentified change of a
noncollected factor over time in one or the other unit.
Whereas the 3GC-RE-related HAI incidence rate was
high during period 1, it might have decreased during
period 2, even in the absence of intervention. Neverthe-
less, we can hypothesize that the decreased workload as-
sociated with targeted screening led to increased infection
control compliance regarding 3GC-RE-colonized patients.
3GC-REs are due mainly to ESBL on one hand and
overproduction of cephalosporinase on the other hand.
Whereas ESBLs are carried by mobile elements, cepha-
losporinases have mainly chromosomal support. How-
ever, plasmid-mediated cephalosporinases have been
described in the literature. For example, in a French
multicentre ICU study of the prevalence and molecular
epidemiology of resistance to 3GCs for E. coli, 41 3GC-
R E. coli were isolated, of which 19 (46.3%) strains were
ESBL-producing E.coli and 18 (43.9%) were the AmpC
phenotype. Among these 18 strains, 5 (27.8%) of the
plasmids carried AmpC enzyme [44]. Regarding the cost
and workload required for ESBL diagnoses, notably in
bacteria among ESBL that could be masked by cephalos-
porinase, and the emergence of plasmid mediated cepha-
losporinases, the lack of distinction between ESBL-E and
3GC-RE is a minor limitation of the study. Between
2008 and 2011, the proportions of ESBLs in clinical sam-
ples were 84.2% in unit A (144 of 171 clinical samples)
and 70.8% in unit B (68 of 96 clinical samples).Conclusions
Our study results indicate that the implementation of a
relatively simple procedure, consisting of targeted
screening for 3GC-RE at ICU admission for transferred
patients, does not increase the 3GC-RE-related HAI in-
cidence rate. Universal screening for 3GC-RE requires
human and financial resources [36], and targeted screen-
ing may be worth further assessment as an alternative to
universal screening. However, it remains difficult to rec-
ommend such a strategy before robust evidence of pro-
portions of patient-to-patient transmission acquired in
multicentre studies has been provided. In addition, con-
trolled and cost-effectiveness studies are warranted to
confirm potential interest in targeted screening for 3GC-
RE at admission.Key messages
 The efficacy of universal screening to detect 3GC-RE
carriers at ICU admission on the 3GC-RE HAI
incidence rates is imperfectly known and seems not to
be cost-effective, particularly if patient-to-patient
transmission or prevalence at admission is low.
 The aim of the study was to evaluate the impact of
targeted screening for 3GC-RE at ICU admission on
the 3GC-RE HAI incidence rate and compare it to
universal screening.
 A quasi-experimental study with intervention and
control groups showed that the implementation of
targeted screening for 3GC-RE at ICU admission for
patients transferred from another unit or hospital
does not involve an increase of 3GC-RE HAI
incidence over time.
 An 85% decrease in the total number of rectal
samples was observed.
 Targeted screening may be worthy of further
assessment as an alternative to universal screening.Abbreviations
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